ReviewOncology letters2020
The role of long non-coding RNA H19 in breast cancer.
Review in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- The interplay of the lncRNA AFAP1-AS1 and the soluble immune checkpoint proteins sPD-1/sPD-L1 in breast cancer: tumor-immune cross-talk.Bioscience reports · 2026Article
- Investigation of Long Non-Coding RNAsNon-coding RNA · 2026Article
- Long non-coding RNAs and accelerated aging in bipolar disorder.Neuroscience applied · 2026Review
- Exploring the Role of Long Noncoding RNAs in Breast Cancer Progression: A Comprehensive Study on Biomarkers and Therapeutic Approaches.Cancer medicine · 2026Review
- A Snapshot of the Role of Estrogen-Regulated Divergent Non-Coding Transcripts.Clinical and translational discovery · 2025Article
- The Effect and Treatment of PIK3CA Mutations in Breast Cancer: Current Understanding and Future Directions.Medicina (Kaunas, Lithuania) · 2025Review
- Epigenetic alterations in triple-negative breast cancer and their clinical implications for diagnosis and therapy.Journal of Cancer · 2025Review
- METTL3-mediated m6A methylation on lncRNA H19 inhibits intrahepatic cholangiocarcinoma progression through PPARγ downregulation.International journal of biological sciences · 2025Article
- The Role of Long Non-Coding RNAs in Ovarian Cancer Cells.International journal of molecular sciences · 2024Review
- Impact of Molecular Profiling on Therapy Management in Breast Cancer.Journal of clinical medicine · 2024Review
- Epigenetic modulation of long noncoding RNA H19 in oral squamous cell carcinoma-A narrative review.Non-coding RNA research · 2024Review
- All-trans-retinoic acid modulates glycolysis via H19 and telomerase: the role of mir-let-7a in estrogen receptor-positive breast cancer cells.BMC cancer · 2024Article
- Interaction between lncRNAs and RNA-binding proteins (RBPs) influences DNA damage response in cancer chemoresistance.Molecular biology reports · 2024Review
- Review
- Influence of H19 polymorphisms on breast cancer: risk assessment and prognostic implications via LincRNA H19/miR-675 and downstream pathways.Frontiers in oncology · 2024Article
- H19: An Oncogenic Long Non-coding RNA in Colorectal Cancer.The Yale journal of biology and medicine · 2023Review
- A review on the biological roles of LncRNA PTCSC3 in cancerous and non-cancerous disorders.Cancer cell international · 2023Review
- The role of long noncoding RNA H19 in gynecological pathologies: Insights into gene regulation and immune modulation (Review).International journal of molecular medicine · 2023Review
- Long noncoding RNA (lncRNA)Genes & diseases · 2023Review
- Molecular hallmarks of long non-coding RNAs in aging and its significant effect on aging-associated diseases.Neural regeneration research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common malignant tumor in women in the majority of countries, such as China, Britain and Australia, and its morbidity and mortality rates remain very high. Long non-coding RNAs (lncRNAs) are non-coding RNAs (ncRNAs) >200 nucleotides in length that lack open reading frames. LncRNA H19 is a transcription product of the H19 gene, and the aberrant expression of H19 can be demonstrated in various types of tumor cell. The purpose of the present review was to elaborate the role of H19 in breast cancer. H19 can regulate gene expression in breast cancer at multiple levels, including epigenetic, transcriptional and posttranscriptional. The abnormal expression of H19 is closely associated with the tumorigenesis and progression of breast cancer via different underlying molecular mechanisms, such as encoding microRNA-675, competing endogenous RNA regulation and interacting with MYC. A large number of clinical studies have suggested that H19 can serve as a potential biomarker for the diagnosis of breast cancer. High expression levels of H19 increases the drug resistance of breast cancer cells and is associated with poor prognosis within patients with breast cancer. Therefore, serum H19 levels may have momentous significance in the clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.